UTM Stock Chart & Stats
€59.50
-€4.50(-7.56%)
At close: 4:00 PM EDT
€59.50
-€4.50(-7.56%)
Day’s Range― - ―
52-Week Range€45.60 - €64.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€205.01M
Enterprise Value€132.30
Total Cash (Recent Filing)€87.53M
Total Debt (Recent Filing)€195.00K
Price to Earnings (P/E)22.5
Beta0.41
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.28
Shares Outstanding3,183,818
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)1.52
Price to Sales (P/S)4.71
P/FCF Ratio12.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityUTMD’s high gross and net margins indicate meaningful profitability in its regulated medical-device portfolio. Maintaining this margin quality supports internal funding for product development, sales infrastructure, and acquisitions while providing resilience if procedure volumes fluctuate.
High-Quality Cash ConversionCash generation closely tracks reported earnings, showing that UTMD’s profitability converts efficiently into funds available for reinvestment, acquisitions, dividends, or balance-sheet strengthening. This supports financial self-reliance and reduces dependence on external financing for future initiatives.
Conservative Balance SheetA near-debt-free capital structure limits solvency and refinancing exposure, leaving UTMD substantial flexibility to withstand operating pressure or pursue targeted growth. The conservative balance sheet also allows cash-funded strategic investments without materially increasing financial risk.
Bears Say
Persistent Revenue ContractionRepeated revenue declines point to weakening demand or market momentum across UTMD’s served product areas rather than a single quarterly fluctuation. Continued contraction could reduce operating leverage, constrain investment capacity, and make stable earnings increasingly dependent on margins.
Shrinking Free Cash FlowAlthough UTMD still produces positive cash flow, the downward trend reduces the resources available for acquisitions, shareholder returns, and product investment. If the contraction persists alongside weaker revenue, it could gradually erode the company’s ability to fund growth internally.
Deteriorating Return ProfileLower margins and declining return on equity suggest that the business is generating less economic output from its operations and capital base than in earlier years. Persistent deterioration would weaken earnings quality over time, even though absolute profitability remains strong.
Utah Medical Products News
UTM FAQ
What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was €45.60 and its highest was €64.00 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is €205.01M.
When is Utah Medical Products’s upcoming earnings report date?
Utah Medical Products’s upcoming earnings report date is Oct 27, 2026 which is in 36 days.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Jul 23, 2026. The company reported €0.732 earnings per share for the quarter.
Is Utah Medical Products overvalued?
According to Wall Street analysts Utah Medical Products’s price is currently Overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products does not currently pay dividends.
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 3,183,818 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of €0.732 in its last earnings report. Following the earnings report the stock price went up 1.71%.
Which hedge fund is a major shareholder of Utah Medical Products?
Currently, no hedge funds are holding shares in DE:UTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Utah Medical Products Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
DE:UTM Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.82%
12-Months-Change
Fundamentals
Return on Equity
1.66%
Trailing 12-Months
Asset Growth
3.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Utah Medical Products
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.